Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial

High-grade gliomas have a poor prognosis and do not respond well to treatment. Effective cancer immune responses depend on functional immune cells, which are typically absent from the brain. This study aimed to evaluate the safety and activity of two adenoviral vectors expressing HSV1-TK (Ad-hCMV-TK...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2023-09, Vol.24 (9), p.1042-1052
Hauptverfasser:	Umemura, Yoshie, Orringer, Daniel, Junck, Larry, Varela, Maria L, West, Molly E J, Faisal, Syed M, Comba, Andrea, Heth, Jason, Sagher, Oren, Leung, Denise, Mammoser, Aaron, Hervey-Jumper, Shawn, Zamler, Daniel, Yadav, Viveka N, Dunn, Patrick, Al-Holou, Wajd, Hollon, Todd, Kim, Michelle M, Wahl, Daniel R, Camelo-Piragua, Sandra, Lieberman, Andrew P, Venneti, Sriram, McKeever, Paul, Lawrence, Theodore, Kurokawa, Ryo, Sagher, Karen, Altshuler, David, Zhao, Lili, Muraszko, Karin, Castro, Maria G, Lowenstein, Pedro R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviruses Adolescent Adult Adverse events Aged Antineoplastic Agents Brain cancer Brain research Chemoradiotherapy Clinical trials Cytomegalovirus Cytotoxicity Dendritic cells Drug dosages Expression vectors Female FLT3L protein Gene therapy Genetic Therapy Glioblastoma Glioblastoma - genetics Glioblastoma - therapy Glioma Glioma - genetics Glioma - therapy Herpes viruses Humans Immune response Immunotherapy Kinases Ligands Male Medical prognosis Middle Aged Oncology Patients Thromboembolism Toxicity Tuberculin Valacyclovir Vectors (Biology) Wound infection
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!